Adial Pharmaceuticals Inc (NASDAQ:ADIL) Reports Intended Expansion Of AD04

Adial Pharmaceuticals Inc (NASDAQ:ADIL) reported plans to grow
activities around the firm’s lead asset named AD04, beyond AUD, to now include
its prospective use in people with opioid use disorder. William Stilley, the CEO,
expressed that they are expanding their activities around lead asset to include
opioid use disorder and consider this program has notable potential since the
neuro-transmitters and physiology involved in opioid addiction are not
different than alcohol and could be anticipated to be controlled by a serotonin-3
receptor antagonist.T

As per the Centers for Disease
control, in this year itself, over 72,000 people in the U.S. died of drug
overdoses. This recorded the highest number of people in U.S. who ever deceased
of drug overdoses in a year, more than those died by car crashes, HIV/AIDS or
guns. The CEO of Adial expressed that AUD is an immensely underserved market. Among
opioids, fentanyl marks as the leading driver of overdose deaths in U.S.

Fentanyl is almost 100 times stronger
than morphine and 50 times more potent than heroin. In 2016, synthetic opioids
passed prescription opioids as the prevalent drugs linked with overdose deaths
in the U.S. Since fentanyl marks as a synthetic opioid, they consider AD04
represents a prospective treatment alternative for these patients as well.

Mr. Stilley further added that they
commend the White House’s initiatives to limit the over prescription of
opioids, and the flow of prohibited synthetic opioids. Also, it is important
that they look after the demand for the drugs, which is led by addiction. This
makes it vital that they start to cure addiction as a ailment and recognize
both the genetic and biological factors leading to this epidemic.

Adial is a clinical-stage biopharma
firm focused on the advancement of treatments for addictions. The firm’s major
investigational new drug offering, AD04, marks as a genetically targeted
therapeutic agent targeting alcohol use disorder. A Phase IIb clinical study of
AD04 for the cure of AUD demonstrated promising results in lowering frequency
of drinking, heavy drinking and quantity of drinking and no explicit safety
concerns.